Poolbeg Pharma PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeremy Skillington
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- The Clubhouse Holborn London GL United Kingdom EC4A 3AG
- IPO Date
- Jul 19, 2021
- Website
- poolbegpharma.com
- Similar Companies
- Business
- Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative medicines targeting serious diseases with high unmet medical needs. Its core products include POLB 001, a first-in-class small molecule immunomodulator designed to prevent and treat cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and severe influenza by reducing the immune system's overreaction. The company also develops POLB 002, an intranasally delivered RNA-based immunotherapy with broad-spectrum antiviral potential against respiratory viruses such as influenza, respiratory syncytial virus (RSV), and SARS-CoV-2; an oral encapsulated GLP-1 receptor agonist targeting obesity and diabetes; and POLB 003, an intramuscular vaccine candidate for Melioidosis. Poolbeg Pharma leverages AI-led discovery programs utilizing data from human challenge trials to identify novel drug targets, enabling faster and more cost-effective drug development. The company also holds licenses for oral vaccine delivery platforms and biomarker and vaccine discovery platforms. Founded in 2021 and headquartered in London, United Kingdom, Poolbeg operates primarily in the biopharmaceutical and biotechnology sectors. In the last 1-2 years, Poolbeg Pharma has made significant advances including securing orphan drug designation from the U.S. FDA for POLB 001, enhancing its commercial appeal and fast-track development potential. The company raised approximately £4.865 million through an oversubscribed equity raise to progress clinical trials and advance its pipeline. Poolbeg has recently expanded its strategic collaborations, notably signing a strategic partnership with a Nasdaq-listed biopharma company to explore new treatment markets. The company continues to advance POLB 001 into Phase 2a clinical trials with interim data expected by 2026 and initiated trials of its oral GLP-1 program targeting metabolic conditions. Additionally, Poolbeg has incorporated AI technology collaborations to identify multiple novel influenza and RSV drug targets, further broadening its clinical and product pipeline. The company is strengthening its rare and orphan disease portfolio, for example through an exclusive option agreement for tPTX, a novel treatment for Behçet’s Disease with FDA Orphan Drug and Fast Track status. Poolbeg’s focus on immunology, infectious diseases, oncology, and metabolic conditions positions it for potential partnering and commercialization opportunities in global markets.
Company News
Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
Poolbeg Pharma doses eight patients in cancer side-effect trial
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
Poolbeg Pharma trial progress strengthens Cavendish case for 19p target
Poolbeg Pharma gets green light to continue clinical trial
Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
Poolbeg doses first patient in cancer immunotherapy safety trial
Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
Poolbeg Pharma shows clinical progress with latest updates
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset